Jannik Andersen - Tango Therapeutics Chief Officer
| TNGX Stock | USD 3.94 0.14 3.43% |
Executive
Jannik Andersen is Chief Officer of Tango Therapeutics
| Address | 201 Brookline Avenue, Boston, MA, United States, 02215 |
| Phone | 857 320 4900 |
| Web | https://www.tangotx.com |
Tango Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2237) % which means that it has lost $0.2237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4879) %, meaning that it created substantial loss on money invested by shareholders. Tango Therapeutics' management efficiency ratios could be used to measure how well Tango Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.34 in 2024. At this time, Tango Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.15 in 2024, whereas Total Assets are likely to drop slightly above 352.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Stuart Henderson | Passage Bio | N/A | |
| Suresh Silva | Shattuck Labs | N/A | |
| David Wustrow | RAPT Therapeutics | 65 | |
| Katarina MD | Xilio Development | 48 | |
| Paul McInulty | Arvinas | N/A | |
| Conor CPA | Shattuck Labs | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Anna Rivkin | Foghorn Therapeutics | N/A | |
| Alan CPA | Tyra Biosciences | 67 | |
| Jeff Boyle | Arvinas | N/A | |
| Kelli MS | Shattuck Labs | N/A | |
| Gregory Fuest | Passage Bio | N/A | |
| Kevin Brennan | Xilio Development | 54 | |
| Erin Graves | Revolution Medicines | N/A | |
| Sarah Honig | Tyra Biosciences | N/A | |
| Eden Fucci | Passage Bio | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| John Northcott | Arvinas | 46 | |
| Steven Sweeney | Third Harmonic Bio | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.22 |
Tango Therapeutics Leadership Team
Elected by the shareholders, the Tango Therapeutics' board of directors comprises two types of representatives: Tango Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tango. The board's role is to monitor Tango Therapeutics' management team and ensure that shareholders' interests are well served. Tango Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tango Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD Kaelin, Founder Board | ||
| Antoni MD, Founder Board | ||
| Barbara MD, CEO President | ||
| Daniella CPA, Chief Officer | ||
| Alan Huang, Chief Officer | ||
| Levi MD, Founder | ||
| JD Esq, Chief Counsel | ||
| Heather MS, Chief Officer | ||
| Alan FRS, Founder Board | ||
| Michael Palmieri, Manufacturing, Chemistry | ||
| Jannik Andersen, Chief Officer | ||
| John MS, Vice Resources | ||
| Charles Davis, Senior Pharmacology | ||
| Timothy Redfern, Chief Officer |
Tango Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tango Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.84) % | ||||
| Operating Margin | (2.83) % | ||||
| Current Valuation | 182.61 M | ||||
| Shares Outstanding | 107.42 M | ||||
| Shares Owned By Insiders | 12.84 % | ||||
| Shares Owned By Institutions | 87.16 % | ||||
| Number Of Shares Shorted | 7.11 M | ||||
| Price To Book | 1.91 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.